TheEdgeResearch
Home / Stocks / NREF

NexPoint Real Estate Finance, Inc. (NREF)

NYSE Real Estate REIT - Mortgage
$15.81 ▼ -3.54%
Market Cap
$298.0M
Sector
Real Estate
Industry
REIT - Mortgage
Beta
1.15
52-Wk Range
12.36-18.43
CEO
James David Dondero
Country
US
Currency
USD

NexPoint Real Estate Finance, Inc. operates in the REIT - Mortgage industry of the Real Estate sector, headquartered in Dallas, TX, US. The stock last traded at $15.81, down 3.54% on the session, giving a market capitalisation of $298.0M. On trailing twelve-month figures it carries a trailing P/E of 4.42, a net margin of 75.0%. Its beta of 1.15 implies it has historically moved more than the broad market.

Valuation & profitability (TTM)
P/E
4.42
Price / Sales
2.22
Price / Book
0.78
EV / EBITDA
29.19
Gross margin
86.4%
Operating margin
112.9%
Net margin
75.0%
Return on equity
Debt / equity
11.79
Current ratio
1.28
Dividend yield
12.7%
Payout ratio
73.1%
Company profile
Exchange
New York Stock Exchange
Employees
1
IPO date
2020-02-07
Headquarters
Dallas, TX, US
About NexPoint Real Estate Finance, Inc.

NexPoint Real Estate Finance, Inc. (NREF) is a U.S.-based real estate finance firm. Its core activities involve the origination, structuring, and investment in a diverse range of real estate-backed financial products. These encompass senior mortgage debt, mezzanine debt, preferred equity, preferred stock, and securitized multifamily commercial mortgage-backed securities. The company aims to qualify as a Real Estate Investment Trust (REIT) for U.S. federal income tax purposes. This status generally allows it to avoid federal corporate income taxes, provided it distributes at least 90% of its taxable earnings to its shareholders. Established in 2019, NREF is headquartered in Dallas, Texas.

Comparable companies

NexPoint Real Estate Finance, Inc. is most often compared with the following Real Estate names:

ACRACREAOMRMITNMITTREFISRGWHLR
More research on NREF
NREF technical analysis NREF TheEdge Score Compare against peers
Open full interactive analysis & DCF →